ReviewCirculation research2022
Cardiovascular Implications of Immune Disorders in Women.
Review in Circulation research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06865885 (Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Systematic review and meta-analysis of cardiovascular associated biomarkers in adults with asymptomatic autoimmune diseases.Frontiers in cardiovascular medicine · 2025Pooled it
- Early life exposure to ambient particulate matter and Kawasaki disease: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Cardiovascular disease in women: traditional and sex-specific risk factors.European heart journal · 2026Review
- Acute coronary syndromes across the lifespan of women.NPJ cardiovascular health · 2026Review
- Sex and gender differences in responses to antianemic therapies: biological mechanisms and clinical implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Immune Checkpoint Inhibitors, Atherosclerotic Cardiovascular Events, and Plaque Progression Among Women With Cancer.Journal of the American Heart Association · 2026Article
- Inflammaging and Cardiovascular Risk in Old Women.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Association of novel lipid markers with cardiovascular and cerebrovascular disease risk: A cross-sectional NHANES 1999 to 2018 study.Medicine · 2026Article
- Prognostic significance of pan-immune-inflammatory value in adverse cardiovascular and cerebrovascular events post-percutaneous coronary intervention in diabetic patients with coronary heart disease.Frontiers in cardiovascular medicine · 2026Article
- Sex-related disparities in hyperlipidaemia and cardiovascular risk in Sri Lanka: a cross-sectional study.Lipids in health and disease · 2025Article
- Optic neuritis and risk of heart failure and atrial fibrillation: A nationwide cohort study.PNAS nexus · 2025Article
- Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis.Journal of clinical medicine · 2025Review
- Underpinnings of heart failure with preserved ejection fraction in women - From prevention to improving function. A co-publication with the American Journal of Preventive Cardiology and the Journal of Cardiac Failure.American journal of preventive cardiology · 2025Article
- Lifestyle medicine pillars for women's heart health.American journal of preventive cardiology · 2025Article
- Development and validation of a machine learning model for predicting vulnerable carotid plaques using routine blood biomarkers and derived indicators: insights into sex-related risk patterns.Cardiovascular diabetology · 2025Article
- Sex differences in the chronic autoimmune response to myocardial infarction.Clinical science (London, England : 1979) · 2025Article
- The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.Lancet (London, England) · 2025Review
- Genetic association with autoimmune diseases identifies molecular mechanisms of coronary artery disease.iScience · 2024Article
- Cardio-rheumatology: the cardiovascular, pharmacological, and surgical risks associated with rheumatological diseases in women.Canadian journal of physiology and pharmacology · 2024Review
- The Development of a Chest-Pain Protocol for Women Presenting to the Emergency Department.CJC open · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
Immune responses differ between men and women, with women at higher risk of developing chronic autoimmune diseases and having more robust immune responses to many viruses, including HIV and hepatitis C virus. Although immune dysregulation plays a prominent role in chronic systemic inflammation, a key driver in the development of atherosclerotic cardiovascular disease (ASCVD), standard ASCVD risk prediction scores underestimate risk in populations with immune disorders, particularly women. This review focuses on the ASCVD implications of immune dysregulation due to disorders with varying global prevalence by sex: autoimmune disorders (female predominant), HIV (male-female equivalent), and hepatitis C virus (male predominant). Factors contributing to ASCVD in women with immune disorders, including traditional risk factors, dysregulated innate and adaptive immunity, sex hormones, and treatment modalities, are discussed. Finally, the need to develop new ASCVD risk stratification tools that incorporate variables specific to populations with chronic immune disorders, particularly in women, is emphasized.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.